ANL 32.50 Decreased By ▼ -0.30 (-0.91%)
ASC 14.38 Decreased By ▼ -0.22 (-1.51%)
ASL 22.65 Decreased By ▼ -0.24 (-1.05%)
AVN 86.95 Decreased By ▼ -0.93 (-1.06%)
BOP 7.92 Decreased By ▼ -0.05 (-0.63%)
BYCO 9.94 Decreased By ▼ -0.02 (-0.2%)
DGKC 116.00 Decreased By ▼ -0.20 (-0.17%)
EPCL 52.50 Decreased By ▼ -1.00 (-1.87%)
FCCL 23.25 Decreased By ▼ -0.43 (-1.82%)
FFBL 26.65 Decreased By ▼ -0.90 (-3.27%)
FFL 15.20 Decreased By ▼ -0.10 (-0.65%)
HASCOL 9.15 Decreased By ▼ -0.10 (-1.08%)
HUBC 75.50 Decreased By ▼ -1.00 (-1.31%)
HUMNL 6.15 Decreased By ▼ -0.04 (-0.65%)
JSCL 20.15 Decreased By ▼ -0.36 (-1.76%)
KAPCO 38.10 Decreased By ▼ -0.60 (-1.55%)
KEL 3.70 Decreased By ▼ -0.06 (-1.6%)
LOTCHEM 15.00 Decreased By ▼ -0.50 (-3.23%)
MLCF 42.99 Decreased By ▼ -0.76 (-1.74%)
PAEL 32.57 Decreased By ▼ -0.13 (-0.4%)
PIBTL 10.00 Increased By ▲ 0.05 (0.5%)
POWER 8.79 Increased By ▲ 0.14 (1.62%)
PPL 82.30 Decreased By ▼ -1.00 (-1.2%)
PRL 24.10 Increased By ▲ 0.05 (0.21%)
PTC 9.11 Decreased By ▼ -0.04 (-0.44%)
SILK 1.33 Decreased By ▼ -0.03 (-2.21%)
SNGP 39.10 Decreased By ▼ -0.25 (-0.64%)
TRG 176.00 Increased By ▲ 5.00 (2.92%)
UNITY 30.75 Decreased By ▼ -0.50 (-1.6%)
WTL 1.55 Increased By ▲ 0.03 (1.97%)
BR100 4,795 Decreased By ▼ -29.74 (-0.62%)
BR30 24,960 Decreased By ▼ -99.54 (-0.4%)
KSE100 44,707 Decreased By ▼ -222.85 (-0.5%)
KSE30 18,276 Decreased By ▼ -98.7 (-0.54%)

Coronavirus
VERY HIGH
Pakistan Deaths
16,842
14424hr
Pakistan Cases
784,108
587024hr
Sindh
275,815
Punjab
282,469
Balochistan
21,365
Islamabad
72,150
KPK
110,875
World

US biotech firm Inovio reports encouraging virus vaccine results

  • Inovio's vaccine, called INO-4800, is designed to inject DNA into a person so as to set off a specific immune system response against the SARS-CoV-2 virus.
30 Jun 2020

WASHINGTON: The US biotech firm Inovio reported preliminary but encouraging results Tuesday from tests of an experimental coronavirus vaccine.

Administered to 40 volunteers, it triggered an immune system response in 94 percent of those who completed the so-called phase one clinical trial, meaning they received two injections, four weeks apart.

Inovio's vaccine, called INO-4800, is designed to inject DNA into a person so as to set off a specific immune system response against the SARS-CoV-2 virus.

The medication is injected under the skin with a needle, then activated with a device that resembles a toothbrush, which delivers an electrical impulse for a fraction of a second, allowing the DNA to penetrate the body's cells and carry out its mission.

Inovio, which is financed by the US Defense Department and the NGO CEPI, also said it has been included in President Donald Trump's plan to produce hundreds of millions of doses of the vaccine by January as part of Operation Warp Speed.

Inovio's medication is the only DNA vaccine that is stable at room temperature for more than a year and does not need refrigeration for transport or storage for several years, said Inovio CEO Joseph Kim.

This is a big plus when it comes to vaccinating people in developing countries, where it is harder to maintain the cold chain needed to preserve many products.

A total of 23 COVID-19 vaccine projects have launched clinical trials on humans, says the London School of Hygiene & Tropical Medicine, and several have moved to phase two or three, which means they are being injected into thousands or even tens of thousands of volunteers.

A vaccine created by the US biotech firm Moderna and one from Oxford University in collaboration with British-Swedish firm AstraZeneca are among those which are in the most advanced stages of development, as are several Chinese projects. These include one from the company CanSinoBIO, which has received permission to administer the vaccine to Chinese soldiers.